Application Note
*Optimal dilutions/concentrations should be determined by the researcher.
| Application |
Recommended Dilution |
| 0.1-0.2 μg/ml |
| 3-10 μg/ml |
| 5-15 μg/ml |
| 0.1-0.3 μg/ml |
|
Note :
WB
using protease-digested sections of human and mouse skeletal muscle.
FACS
using protease-digested sections of mouse brown adipose tissue.
IHC
using mitochondrial extract of rat brown adipose tissue
|
Not tested in other applications.
Product Note
The antibody has the ability to neutralize the biological activity of recombinant mouse VEGF R2. It demonstates approximately 40% cross-reactivity with recombinant human VEGF R2, 2% cross-reactivty with recombinant mouse VEGF R1, and no cross-reactivity with recombinant human VEGF R1 and VEGF R3.
Form
Liquid
Buffer
PBS carbohydrates
Preservative
No preservative
Storage
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
Concentration
Batch dependent (Please refer to the vial label for the specific concentration.)
Antigen Species
Mouse
Immunogen
purified recombinant mouse VEGF R2 extracellular domain expressed in NSO cells.
Purification
Purified by affinity chromatography
Conjugation
Unconjugated
RRID
AB_378046
Note
For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.
Synonyms
kinase insert domain protein receptor , 6130401C07 , Flk-1 , Flk1 , Krd-1 , Ly73 , VEGFR-2 , VEGFR2 , orv , sVEGFR-2
Background
Vascular endothelial growth factors (VEGFs) are a family of closely related growth factors having a conserved pattern of eight cysteine residues and sharing common VEGF receptors. VEGFs stimulate the proliferation of endothelial cells, induce angiogenesis, and increase vascular permeability in both large and small vessels. The mitogenic activity of VEGFs appears to be mediated by specific VEGF receptors. Vascular Endothelial Growth Factor Receptor 2 (VEGF Receptor 2, KDR, Flk1) is one of the five receptor tyrosine kinases (RTKs) (VEGF Receptor 1/Flt1, VEGF Receptor 2/KDR/Flk1, VEGF Receptor 3/Flt4, tie1 and tek/tie2) whose expression is almost exclusively restricted to endothelial cells. These RTKs play central roles in vasculogenesis and angiogenesis. Tie1 and tek/tie2 are a class of RTKs containing two immunoglobulin-like domains, three EGF homology domains and three fibronectin type III domains in their extracellular regions. VEGF Receptor 1/Flt1, VEGF Receptor 2/KDR/Flk1, and VEGF Receptor 3/Flt4 are members of the class III subfamily of RTKs containing seven immunoglobulin-like repeats in their extracellular domains. VEGF Receptor 1 and VEGF Receptor 2 are both expressed in an endothelial cell-specific manner. They are detectable in virtually all tissues in adults and embryos. Monocytes express VEGF Receptor 1 and VEGF Receptor 2. VEGF Receptor 2 is also expressed in pancreatic duct cells, hematopoietic stem cells, megakaryocytes, specific tumor cell types such as malignant melanoma cells, and retinal progenitor cells. In the retina, two functional VEGF Receptor 2 forms are expressed as a result of alternative splicing. VEGF Receptor 2 is a key marker for pluripotent hematopoietic stem cells. VEGF Receptor 1 and VEGF Receptor 2 are closely related in their putative roles in angiogenesis. VEGF Receptor 2 is involved in commitment of endothelial-cell lineages and to cell proliferation, while VEGF Receptor 1 seems to be responsible for guiding endothelial cells into the proper spatial organization of the lumen-containing vessels. VEGF Receptor 1 binds both PIGF and VEGF with high affinity, whereas VEGF Receptor 2 binds VEGF with high affinity but does not bind PIGF. Recombinant soluble VEGF Receptor 2/Fc chimera binds VEGF with high affinity and is a potent VEGF antagonist.
Database
Research Area
